Gautam U Mehta1, Shaan M Raza2, Shirley Y Su3, Ehab Y Hanna3, Franco DeMonte4,5. 1. Division of Neurosurgery, House Clinic, Los Angeles, CA, USA. 2. Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 3. Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 4. Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. fdemonte@mdanderson.org. 5. Department of Neurosurgey, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Blvd, Room FC7.200, Unit 442, Houston, TX, 77030-4009, USA. fdemonte@mdanderson.org.
Abstract
INTRODUCTION: Sinonasal tumors that harbor neuroendocrine histologic features include olfactory neuroblastoma (previously known as esthesioneuroblastoma), sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma. These tumors represent a diverse spectrum of clinical behavior and as such require histology-specific management. Herein, we review the management of these sinonasal tumors with neuroendocrine features and discuss fundamentals of multi-modality care for each histology. An emphasis is placed on olfactory neuroblastomas, given their relative frequency and skullbase origin. METHODS: A comprehensive literature review on contemporary management of olfactory neuroblastoma, sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma was performed. RESULTS: Management of sinonasal tumors with neuroendocrine features can include surgical resection, radiation therapy, and/or chemotherapy. Due to their site of origin, these tumors can frequently involve the skullbase, which can require site-specific care. The optimal treatment modalities and the sequence in which they are performed are largely dependent on histology. In most cases, olfactory neuroblastoma is best managed with surgical resection followed by radiation therapy. Sinonasal neuroendocrine carcinomas represent a variety of histologic phenotypes (carcinoid, atypical carcinoid, small cell, and large cell), which determine the optimal treatment modality. Finally, sinonasal undifferentiated carcinoma is likely best managed by induction chemotherapy with subsequent therapy dictated by the initial response. CONCLUSIONS: A team approach to multi-modality care is essential in the treatment of olfactory neuroblastoma, sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma. Early biopsy, histologic diagnosis, and comprehensive imaging are critical to determining the appropriate management paradigm.
INTRODUCTION:Sinonasal tumors that harbor neuroendocrine histologic features include olfactory neuroblastoma (previously known as esthesioneuroblastoma), sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma. These tumors represent a diverse spectrum of clinical behavior and as such require histology-specific management. Herein, we review the management of these sinonasal tumors with neuroendocrine features and discuss fundamentals of multi-modality care for each histology. An emphasis is placed on olfactory neuroblastomas, given their relative frequency and skullbase origin. METHODS: A comprehensive literature review on contemporary management of olfactory neuroblastoma, sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma was performed. RESULTS: Management of sinonasal tumors with neuroendocrine features can include surgical resection, radiation therapy, and/or chemotherapy. Due to their site of origin, these tumors can frequently involve the skullbase, which can require site-specific care. The optimal treatment modalities and the sequence in which they are performed are largely dependent on histology. In most cases, olfactory neuroblastoma is best managed with surgical resection followed by radiation therapy. Sinonasal neuroendocrine carcinomas represent a variety of histologic phenotypes (carcinoid, atypical carcinoid, small cell, and large cell), which determine the optimal treatment modality. Finally, sinonasal undifferentiated carcinoma is likely best managed by induction chemotherapy with subsequent therapy dictated by the initial response. CONCLUSIONS: A team approach to multi-modality care is essential in the treatment of olfactory neuroblastoma, sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma. Early biopsy, histologic diagnosis, and comprehensive imaging are critical to determining the appropriate management paradigm.
Entities:
Keywords:
Esthesioneuroblastoma; Neuroendocrine carcinoma; Olfactory neuroblastoma; Sinonasal undifferentiated cancer
Authors: Diana Bell; Ehab Y Hanna; Randal S Weber; Franco DeMonte; Asterios Triantafyllou; James S Lewis; Antonio Cardesa; Pieter J Slootweg; Göran Stenman; Douglas R Gnepp; Kenneth O Devaney; Juan P Rodrigo; Alessandra Rinaldo; Bruce M Wenig; William H Westra; Justin A Bishop; Henrik Hellquist; Jennifer L Hunt; Kimihide Kusafuka; Bayardo Perez-Ordoñez; Michelle D Williams; Robert P Takes; Alfio Ferlito Journal: Head Neck Date: 2015-07-18 Impact factor: 3.147
Authors: Diana Bell; Rami Saade; Dianna Roberts; Thomas J Ow; Michael Kupferman; Franco DeMonte; Ehab Y Hanna Journal: Head Neck Pathol Date: 2014-05-08
Authors: Ahmad H Elkhatib; Liuba Soldatova; Ricardo L Carrau; Ralph Abi Hachem; Leo Ditzel; Raewyn Campbell; Daniel M Prevedello; Luciano Prevedello; Leo F S Ditzel Filho; Raewyn G Campbell Journal: Laryngoscope Date: 2016-08-02 Impact factor: 3.325
Authors: Shirley Y Su; Diana Bell; Renata Ferrarotto; Jack Phan; Dianna Roberts; Michael E Kupferman; Steven J Frank; C David Fuller; G Brandon Gunn; Merrill S Kies; Bonnie S Glisson; Ehab Y Hanna Journal: Head Neck Date: 2017-05-31 Impact factor: 3.147
Authors: Rahul Dutta; Pariket M Dubal; Peter F Svider; James K Liu; Soly Baredes; Jean Anderson Eloy Journal: Laryngoscope Date: 2015-07-30 Impact factor: 3.325
Authors: David Capper; Nils W Engel; Damian Stichel; Matt Lechner; Stefanie Glöss; Simone Schmid; Christian Koelsche; Daniel Schrimpf; Judith Niesen; Annika K Wefers; David T W Jones; Martin Sill; Oliver Weigert; Keith L Ligon; Adriana Olar; Arend Koch; Martin Forster; Sebastian Moran; Oscar M Tirado; Miguel Sáinz-Jaspeado; Jaume Mora; Manel Esteller; Javier Alonso; Xavier Garcia Del Muro; Werner Paulus; Jörg Felsberg; Guido Reifenberger; Markus Glatzel; Stephan Frank; Camelia M Monoranu; Valerie J Lund; Andreas von Deimling; Stefan Pfister; Rolf Buslei; Julika Ribbat-Idel; Sven Perner; Volker Gudziol; Matthias Meinhardt; Ulrich Schüller Journal: Acta Neuropathol Date: 2018-05-05 Impact factor: 15.887
Authors: Fernando López; Jatin P Shah; Jonathan J Beitler; Carl H Snyderman; Valerie Lund; Cesare Piazza; Antti A Mäkitie; Orlando Guntinas-Lichius; Juan P Rodrigo; Luiz P Kowalski; Miquel Quer; Ashok Shaha; Akihiro Homma; Alvaro Sanabria; Renata Ferrarotto; Anne W M Lee; Victor H F Lee; Alessandra Rinaldo; Alfio Ferlito Journal: Adv Ther Date: 2022-03-30 Impact factor: 4.070
Authors: Stefanie Glöss; Philipp Jurmeister; Anne Thieme; Simone Schmid; Wei Y Cai; Rene N Serrette; Sven Perner; Julika Ribbat-Idel; Axel Pagenstecher; Hendrik Bläker; Ursula Keber; Christine Stadelmann; Sabrina Zechel; Pascal D Johann; Martin Hasselblatt; Werner Paulus; Christian Thomas; Hildegard Dohmen; Daniel Baumhoer; Stephan Frank; Abbas Agaimy; Ulrich Schüller; Varshini Vasudevaraja; Matija Snuderl; Cheng Z Liu; David G Pfister; Achim A Jungbluth; Ronald A Ghossein; Bin Xu; David Capper; Snjezana Dogan Journal: Am J Surg Pathol Date: 2021-09-01 Impact factor: 6.298